Final FDA user fee bill uses mostly Senate language for antibiotic incentives; House vote is expected Wednesday.
Sanofi has teamed up with the Joslin Diabetes Center, a research affiliate of Harvard Medical School, in a collaboration that will focus on four areas of diabetes to identify new biologic drugs and insulin analogs.
FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will review applications for Genentech's Lucentis (ranibizumab) for diabetic macular edema and ThromboGenics' Jetrea (ocriplasmin intravitreal injection) for symptomatic vitreomacular adhesions, including macular hole, at its July 26 meeting.
FDA plans to conduct a study to determine whether the inclusion of disease information in branded drug advertisements affects consumer perceptions of the product. The study will evaluate direct-to-consumer Rx drug print ads addressing chronic obstructive pulmonary disease, lymphoma and anemia.